Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

AC Immune

Request full access

Clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases

Lausanne, SwitzerlandFounded 2003Biotech & Life Sciences
Valuation $222M Market cap · 2026
Revenue $3.3M Latest reported FY

About AC Immune

AC Immune is a biopharmaceutical company specializing in the development of innovative therapies and diagnostics for neurodegenerative diseases, such as Alzheimer's and Parkinson's. The company operates in the biotechnology sector and primarily serves patients, healthcare providers, and pharmaceutical companies. AC Immune's business model revolves around leveraging its proprietary technology platforms to create a broad pipeline of products aimed at treating and diagnosing neurodegenerative conditions. The company generates revenue through partnerships, licensing agreements, and milestone payments from larger pharmaceutical firms. AC Immune's goal is to become a global leader in precision medicine for neurodegenerative diseases, addressing one of the most significant challenges facing society today.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2003
Headquarters
Lausanne, Switzerland
Listing
IPO 2016
Sector
Biotech & Life Sciences
Outcome tier
Thoroughbred$100M+ revenue

Knowledge graph

Founder mafias, market maps, lists and research connected to this company by Dealroom
Market maps in Biotech & Life Sciences
Market map Rare Disease Therapeutics & Technologies Landscape Market map TechBio x Drug discovery (Europe & Israel) Market map Peptides: The Next Drug Modality Stack Apr 10, 2026

Open roles

Track hiring at AC ImmuneOpen roles, team growth and hiring by functionBook a demo
Looking for a job? The startup jobs board lists open roles.Startups hiring now →

AC Immune in the Lausanne ecosystem

Live from Dealroom

The AC Immune office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later6 investors entered at this stage

  • dievini Hopp Biotech holding
  • Dietmar Hopp
  • Avidity Partners
  • BVF Partners
  • Redmile Group
  • StemPoint Capital

Talent

Book a demo to see the people
Employees mapped 147 incl. 2 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 10 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇨🇭 Switzerland95.3%
🇫🇷 France2.4%
🇩🇪 Germany0.8%
🇬🇧 United Kingdom0.8%
🇦🇹 Austria0.8%
5 countries shown
Web traffic by country
6.2K monthly visits
across markets
🇺🇸 United States41.9%
🇬🇧 United Kingdom25.8%
🇨🇭 Switzerland14.5%
🇮🇳 India14.5%
🇩🇪 Germany1.6%
Top 5 markets shown

Patents

Estimated portfolio value
$230M

112 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about AC Immune on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See AC Immune on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles